Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Puma Biotechnology Inc - Common Stock
(NQ:
PBYI
)
5.100
-0.360 (-6.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Puma Biotechnology Inc - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 23, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Earnings Scheduled For August 7, 2025
August 07, 2025
Via
Benzinga
Earnings Scheduled For May 8, 2025
May 08, 2025
Via
Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 02, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 08, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma (PBYI) Q2 Revenue Rises 11%
August 08, 2025
Via
The Motley Fool
Topics
Intellectual Property
Puma Biotechnology Reports Second Quarter Financial Results
August 07, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results
July 24, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports First Quarter Financial Results
May 08, 2025
From
Puma Biotechnology, Inc..
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
April 28, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
April 24, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
March 26, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
March 05, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
February 26, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
February 13, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 05, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2025
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
December 23, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
November 20, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Third Quarter 2024 Financial Results
November 07, 2024
From
Puma Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today